Mayus Kinase (JAK) Inhibitor -Pipeline Insight, 2020
This report can be delivered to the clients within 48 hours
OVERVIEW
'Mayus Kinase (JAK) Inhibitor - Pipeline Insight, 2020' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the mechanism of action. A detailed picture of the Mayus Kinase (JAK) Inhibitor pipeline landscape is provided, which includes the topic overview and Mayus Kinase (JAK) Inhibitor mechanism of action. The assessment part of the report embraces, in-depth Mayus Kinase (JAK) Inhibitor commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes the product description, mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Mayus Kinase (JAK) Inhibitor pipeline development activities
The report provides insights into:
Mayus Kinase (JAK) Inhibitor Analytical Perspective by DelveInsight
SCOPE OF THE REPORT
OVERVIEW
'Mayus Kinase (JAK) Inhibitor - Pipeline Insight, 2020' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the mechanism of action. A detailed picture of the Mayus Kinase (JAK) Inhibitor pipeline landscape is provided, which includes the topic overview and Mayus Kinase (JAK) Inhibitor mechanism of action. The assessment part of the report embraces, in-depth Mayus Kinase (JAK) Inhibitor commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes the product description, mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Mayus Kinase (JAK) Inhibitor pipeline development activities
The report provides insights into:
- All the companies developing therapies of Mayus Kinase (JAK) Inhibitor with aggregate therapies developed by each company for the same.
- Different therapeutic candidates in early-stage, mid-stage and late stage of development for Mayus Kinase (JAK) Inhibitor.
- Key players involved in Mayus Kinase (JAK) Inhibitor targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Collaborations (company-company collaborations and company-academia collaborations), licensing agreements and financing details for future developments of Mayus Kinase (JAK) Inhibitor.
Mayus Kinase (JAK) Inhibitor Analytical Perspective by DelveInsight
- In-depth Mayus Kinase (JAK) Inhibitor Commercial Assessment of products
- Mayus Kinase (JAK) Inhibitor Clinical Assessment of products
SCOPE OF THE REPORT
- The Mayus Kinase (JAK) Inhibitor report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA the complete product development cycle, including all clinical and nonclinical stages.
- It comprises of detailed profiles of Mayus Kinase (JAK) Inhibitor therapeutic products with key coverage of involved technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details.
- Elucidated Mayus Kinase (JAK) Inhibitor research and development progress and trial details, results wherever available, are also included in the pipeline study.
- Coverage of dormant and discontinued pipeline projects along with the reasons if available across Mayus Kinase (JAK) Inhibitor.
- In the coming years, the Mayus Kinase (JAK) Inhibitor market is set to change due to the extensive research in this filed, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
- The companies and academics are working to assess challenges and seek opportunities that could influence Mayus Kinase (JAK) Inhibitor R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
- There are several companies involved in developing therapies for Mayus Kinase (JAK) Inhibitor. Launch of emerging therapies of Mayus Kinase (JAK) Inhibitor will significantly impact the market.
- A better understanding of the target mechanism will also contribute to the development of novel therapeutics for Mayus Kinase (JAK) Inhibitor.
- Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Mayus Kinase (JAK) Inhibitor) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
- What are the current treatment options available based on the Mayus Kinase (JAK) Inhibitor?
- How many companies are developing therapies by working on Mayus Kinase (JAK) Inhibitor?
- What are the principal therapies developed by these companies in the industry?
- How many therapies are developed by each company for Mayus Kinase (JAK) Inhibitor to treat disease condition?
- How many emerging therapies are in early-stage, mid-stage, and late stage of development for Mayus Kinase (JAK) Inhibitor?
- Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other treatments?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Mayus Kinase (JAK) Inhibitor therapies?
- Which are the dormant and discontinued products and the reasons for the same?
- What is the unmet need for current therapies developed based on this mechanism of action?
- What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Mayus Kinase (JAK) Inhibitor and their status?
- What are the results of the clinical studies and their safety and efficacy?
- What are the key designations that have been granted for the emerging therapies for Mayus Kinase (JAK) Inhibitor?
- How many patents are granted and pending for the emerging therapies of Mayus Kinase (JAK) Inhibitor?
1. REPORT INTRODUCTION
2. MAYUS KINASE (JAK) INHIBITOR
2.1. Mayus Kinase (JAK) Inhibitor Overview
2.2. Mayus Kinase (JAK) Inhibitor Classification
2.3. Mayus Kinase (JAK) Inhibitor Structure
2.4. Mayus Kinase (JAK) Inhibitor Mechanism of Action
2.5. Mayus Kinase (JAK) Inhibitor Application
3. MAYUS KINASE (JAK) INHIBITOR - DELVEINSIGHT'S ANALYTICAL PERSPECTIVE
3.1. In-depth Commercial Assessment
3.1.1. Mayus Kinase (JAK) Inhibitor companies collaborations, Licensing, Acquisition Deal Value Trends
3.1.1.1. Assessment Summary
3.1.2. Mayus Kinase (JAK) Inhibitor Collaboration Deals
3.1.2.1. Company-Company Collaborations (Licensing/Partnering) Analysis
3.1.2.2. Company-University Collaborations (Licensing/Partnering) Analysis
3.1.2.3. Mayus Kinase (JAK) Inhibitor Acquisition Analysis
4. THERAPEUTIC ASSESSMENT
4.1. Clinical Assessment of Pipeline Drugs
4.1.1. Assessment by Phase of Development
4.1.2. Assessment by Product Type (Mono/Combination)
4.1.2.1. Assessment by Stage and Product Type
4.1.3. Assessment by Route of Administration
4.1.3.1. Assessment by Stage and Route of Administration
4.1.4. Assessment by Molecule Type
4.1.4.1. Assessment by Stage and Molecule Type
4.1.5. Assessment by MOA
4.1.5.1. Assessment by Stage and MOA
4.1.6. Assessment by Target
4.1.6.1. Assessment by Stage and Target
5. LATE STAGE PRODUCTS (PHASE-III)
6. MID STAGE PRODUCTS (PHASE-II)
7. EARLY STAGE PRODUCTS (PHASE-I)
8. PRE-CLINICAL PRODUCTS AND DISCOVERY STAGE PRODUCTS
9. INACTIVE PRODUCTS
10. DORMANT PRODUCTS
11. DISCONTINUED PRODUCTS
12. MAYUS KINASE (JAK) INHIBITOR PRODUCT PROFILES
12.1. Drug Name: Company
12.1.1. Product Description
12.1.1.1. Product Overview
12.1.1.2. Mechanism of action
12.1.2. Research and Development
12.1.2.1. Clinical Studies
12.1.3. Product Development Activities
12.1.3.1. Collaboration
12.1.3.2. Agreements
12.1.3.3. Acquisition
12.1.3.4. Patent Detail
12.1.4. Tabulated Product Summary
12.1.4.1. General Description Table
Detailed information in the report
13. MAYUS KINASE (JAK) INHIBITOR KEY COMPANIES
14. MAYUS KINASE (JAK) INHIBITOR KEY PRODUCTS
15. DORMANT AND DISCONTINUED PRODUCTS
15.1. Dormant Products
15.1.1. Reasons for being dormant
15.2. Discontinued Products
15.2.1. Reasons for the discontinuation
16. MAYUS KINASE (JAK) INHIBITOR - UNMET NEEDS
17. MAYUS KINASE (JAK) INHIBITOR - FUTURE PERSPECTIVES
18. MAYUS KINASE (JAK) INHIBITOR ANALYST REVIEW
19. APPENDIX
20. REPORT METHODOLOGY
20.1. Secondary Research
20.2. Expert Panel Validation
2. MAYUS KINASE (JAK) INHIBITOR
2.1. Mayus Kinase (JAK) Inhibitor Overview
2.2. Mayus Kinase (JAK) Inhibitor Classification
2.3. Mayus Kinase (JAK) Inhibitor Structure
2.4. Mayus Kinase (JAK) Inhibitor Mechanism of Action
2.5. Mayus Kinase (JAK) Inhibitor Application
3. MAYUS KINASE (JAK) INHIBITOR - DELVEINSIGHT'S ANALYTICAL PERSPECTIVE
3.1. In-depth Commercial Assessment
3.1.1. Mayus Kinase (JAK) Inhibitor companies collaborations, Licensing, Acquisition Deal Value Trends
3.1.1.1. Assessment Summary
3.1.2. Mayus Kinase (JAK) Inhibitor Collaboration Deals
3.1.2.1. Company-Company Collaborations (Licensing/Partnering) Analysis
3.1.2.2. Company-University Collaborations (Licensing/Partnering) Analysis
3.1.2.3. Mayus Kinase (JAK) Inhibitor Acquisition Analysis
4. THERAPEUTIC ASSESSMENT
4.1. Clinical Assessment of Pipeline Drugs
4.1.1. Assessment by Phase of Development
4.1.2. Assessment by Product Type (Mono/Combination)
4.1.2.1. Assessment by Stage and Product Type
4.1.3. Assessment by Route of Administration
4.1.3.1. Assessment by Stage and Route of Administration
4.1.4. Assessment by Molecule Type
4.1.4.1. Assessment by Stage and Molecule Type
4.1.5. Assessment by MOA
4.1.5.1. Assessment by Stage and MOA
4.1.6. Assessment by Target
4.1.6.1. Assessment by Stage and Target
5. LATE STAGE PRODUCTS (PHASE-III)
6. MID STAGE PRODUCTS (PHASE-II)
7. EARLY STAGE PRODUCTS (PHASE-I)
8. PRE-CLINICAL PRODUCTS AND DISCOVERY STAGE PRODUCTS
9. INACTIVE PRODUCTS
10. DORMANT PRODUCTS
11. DISCONTINUED PRODUCTS
12. MAYUS KINASE (JAK) INHIBITOR PRODUCT PROFILES
12.1. Drug Name: Company
12.1.1. Product Description
12.1.1.1. Product Overview
12.1.1.2. Mechanism of action
12.1.2. Research and Development
12.1.2.1. Clinical Studies
12.1.3. Product Development Activities
12.1.3.1. Collaboration
12.1.3.2. Agreements
12.1.3.3. Acquisition
12.1.3.4. Patent Detail
12.1.4. Tabulated Product Summary
12.1.4.1. General Description Table
Detailed information in the report
13. MAYUS KINASE (JAK) INHIBITOR KEY COMPANIES
14. MAYUS KINASE (JAK) INHIBITOR KEY PRODUCTS
15. DORMANT AND DISCONTINUED PRODUCTS
15.1. Dormant Products
15.1.1. Reasons for being dormant
15.2. Discontinued Products
15.2.1. Reasons for the discontinuation
16. MAYUS KINASE (JAK) INHIBITOR - UNMET NEEDS
17. MAYUS KINASE (JAK) INHIBITOR - FUTURE PERSPECTIVES
18. MAYUS KINASE (JAK) INHIBITOR ANALYST REVIEW
19. APPENDIX
20. REPORT METHODOLOGY
20.1. Secondary Research
20.2. Expert Panel Validation
LIST OF TABLES
Table 1 : Assessment Summary
Table 2 : Company-Company Collaborations (Licensing/Partnering) Analysis
Table 3 : Mayus Kinase (JAK) Inhibitor Acquisition Analysis
Table 4 : Assessment by Phase of Development
Table 5 : Assessment by Product Type (Mono/Combination)
Table 6 : Assessment by Stage and Product Type
Table 7 : Assessment by Route of Administration
Table 8 : Assessment by Stage and Route of Administration
Table 9 : Assessment by Molecule Type
Table 10 : Assessment by Stage and Molecule Type
Table 11 : Assessment by MOA
Table 12 : Assessment by Stage and MOA
Table 13 : Assessment by Target
Table 14 : Assessment by Stage and Target
Table 15 : Late Stage Products (Phase-III)
Table 16 : Mid Stage Products (Phase-II)
Table 17 : Early Stage Products (Phase-I)
Table 18 : Pre-clinical and Discovery Stage Products
Table 19 : Inactive Products
Table 20 : Dormant Products
Table 21 : Discontinued Products
Table 1 : Assessment Summary
Table 2 : Company-Company Collaborations (Licensing/Partnering) Analysis
Table 3 : Mayus Kinase (JAK) Inhibitor Acquisition Analysis
Table 4 : Assessment by Phase of Development
Table 5 : Assessment by Product Type (Mono/Combination)
Table 6 : Assessment by Stage and Product Type
Table 7 : Assessment by Route of Administration
Table 8 : Assessment by Stage and Route of Administration
Table 9 : Assessment by Molecule Type
Table 10 : Assessment by Stage and Molecule Type
Table 11 : Assessment by MOA
Table 12 : Assessment by Stage and MOA
Table 13 : Assessment by Target
Table 14 : Assessment by Stage and Target
Table 15 : Late Stage Products (Phase-III)
Table 16 : Mid Stage Products (Phase-II)
Table 17 : Early Stage Products (Phase-I)
Table 18 : Pre-clinical and Discovery Stage Products
Table 19 : Inactive Products
Table 20 : Dormant Products
Table 21 : Discontinued Products
LIST OF FIGURES
Figure 1 : Structure
Figure 2 : Mechanism
Figure 3 : Mayus Kinase (JAK) Inhibitor companies collaborations, Licensing, Acquisition Deal Value Trends
Figure 4 : Company-Company Collaborations (Licensing/Partnering) Analysis
Figure 5 : Mayus Kinase (JAK) Inhibitor Acquisition Analysis
Figure 6 : Assessment by Phase of Development
Figure 7 : Assessment by Product Type (Mono/Combination)
Figure 8 : Assessment by Stage and Product Type
Figure 9 : Assessment by Route of Administration
Figure 10 : Assessment by Stage and Route of Administration
Figure 11 : Assessment by Molecule Type
Figure 12 : Assessment by Stage and Molecule Type
Figure 13 : Assessment by MOA
Figure 14 : Assessment by Stage and MOA
Figure 15 : Late Stage Products (Phase-III)
Figure 16 : Mid Stage Products (Phase-II)
Figure 17 : Early Stage Products (Phase-I)
Figure 18 : Pre-clinical and Discovery Stage Products
Figure 19 : Inactive Products
Figure 20 : Dormant Products
Figure 21 : Discontinued Products
Figure 22 : Unmet Needs
KEY COMPANIES
Rigel Pharmaceuticals
Aclaris Therapeutics
Asana BioSciences
Theravance Biopharma
Portola Pharmaceuticals
CJ Cheiljedang Corp.
Figure 1 : Structure
Figure 2 : Mechanism
Figure 3 : Mayus Kinase (JAK) Inhibitor companies collaborations, Licensing, Acquisition Deal Value Trends
Figure 4 : Company-Company Collaborations (Licensing/Partnering) Analysis
Figure 5 : Mayus Kinase (JAK) Inhibitor Acquisition Analysis
Figure 6 : Assessment by Phase of Development
Figure 7 : Assessment by Product Type (Mono/Combination)
Figure 8 : Assessment by Stage and Product Type
Figure 9 : Assessment by Route of Administration
Figure 10 : Assessment by Stage and Route of Administration
Figure 11 : Assessment by Molecule Type
Figure 12 : Assessment by Stage and Molecule Type
Figure 13 : Assessment by MOA
Figure 14 : Assessment by Stage and MOA
Figure 15 : Late Stage Products (Phase-III)
Figure 16 : Mid Stage Products (Phase-II)
Figure 17 : Early Stage Products (Phase-I)
Figure 18 : Pre-clinical and Discovery Stage Products
Figure 19 : Inactive Products
Figure 20 : Dormant Products
Figure 21 : Discontinued Products
Figure 22 : Unmet Needs
KEY COMPANIES
Rigel Pharmaceuticals
Aclaris Therapeutics
Asana BioSciences
Theravance Biopharma
Portola Pharmaceuticals
CJ Cheiljedang Corp.
